Literature DB >> 7954453

Frequent loss of heterozygosity on chromosome 9 in adenocarcinoma and squamous cell carcinoma of the esophagus.

L Tarmin1, J Yin, X Zhou, H Suzuki, H Y Jiang, M G Rhyu, J M Abraham, M J Krasna, J Cottrell, S J Meltzer.   

Abstract

Loss of heterozygosity (LOH) affecting chromosome 9p has been shown to occur frequently in head and neck cancer, glioma, mesothelioma, melanoma, lung cancer, and numerous other tumor types. Chromosome 9p is therefore presumed to contain a tumor suppressor gene or genes. Since esophageal cancer shares characteristics with some of the above tumor types, we performed a detailed examination of 60 patients with squamous cell carcinoma or adenocarcinoma of the esophagus for LOH at loci D9S162, IFNA, D9S171, D9S126, D9S104, D9S165, and D9S163. Multiplex polymerase chain reactions were performed with the inclusion of one radiolabeled nucleotide, and products were electrophoresed on denaturing polyacrylamide gels. Thirty-six of the 60 patients (60%) exhibited LOH at one or more loci on chromosome 9p. Eight of 17 patients (47%) with adenocarcinoma manifested LOH, while 28 of 43 (65%) with squamous cell carcinoma showed LOH. LOH was most frequent at loci D9S171 (19 of 23, or 83%) and D9S165 (24 of 32, or 75%). These data support the hypothesis that a tumor suppressor gene or genes located on this portion of chromosome 9p exert(s) an effect on esophageal cancer development.

Entities:  

Mesh:

Year:  1994        PMID: 7954453

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Molecular biology of Barrett's adenocarcinoma.

Authors:  B P Wijnhoven; H W Tilanus; W N Dinjens
Journal:  Ann Surg       Date:  2001-03       Impact factor: 12.969

2.  CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.

Authors:  P Schraml; K Struckmann; R Bednar; W Fu; T Gasser; K Wilber; J Kononen; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

3.  The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Authors:  W M Stadler; O I Olopade
Journal:  Urol Res       Date:  1996

Review 4.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

5.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma.

Authors:  M V González; M L Artímez; L Rodrigo; C López-Larrea; M J Menéndez; V Alvarez; R Pérez; M F Fresno; M J Pérez; A Sampedro; E Coto
Journal:  J Clin Pathol       Date:  1997-03       Impact factor: 3.411

6.  Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.

Authors:  P C Galipeau; L J Prevo; C A Sanchez; G M Longton; B J Reid
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

7.  Recessive oncogenes: current status.

Authors:  Xiang Gao; Kenneth V Honn
Journal:  Pathol Oncol Res       Date:  1995       Impact factor: 3.201

Review 8.  Hepatocarcinogenesis in rodents and humans.

Authors:  T Kitagawa; K Miyasaka; H Kanda; H Yasui; O Hino
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

9.  Non-Invasive Detection of Esophageal Cancer using Genetic Changes in Circulating Cell-Free DNA.

Authors:  Saeid Ghorbian; Ali M Ardekani
Journal:  Avicenna J Med Biotechnol       Date:  2012-01

10.  Qualitative analysis of Adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker.

Authors:  Maryam Zare; Ferdous Rastgar Jazii; Mohammad Reza Alivand; Negin Karimi Nasseri; Reza Malekzadeh; Mansour Yazdanbod
Journal:  BMC Cancer       Date:  2009-01-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.